Table 2.

Number of clinical events and relative risks (95% confidence intervals) for different end points in randomised controlled trials of percutaneous transluminal coronary angioplasty (PCTA) compared with medical treatment in non-acute coronary heart disease

End point and trial	No with end point		Relative risk (95% CI)
	PCTA	Control group
Angina*
Parisi 199217	44/105	60/107	0.75 (0.57 to 0.99)
Sievers 199316	12/44	12/44	1.00 (0.51 to 1.95)
MASS 199518	14/72	49/72	0.29 (0.18 to 0.48)
Folland 199713	24/51	32/50	0.74 (0.52 to 1.05)
RITA-2 199714	375/504	406/514	0.94 (0.88 to 1.01)
Fatal and non-fatal MI
Parisi 1992 17	5/105	3/107	1.69 (0.42 to 6.93)
Sievers 199316	2/44	1/44	2.00 (0.19 to 21.26)
MASS 199518	2/72	2/72	1.00 (0.14 to 6.91)
Folland 199713	2/51	6/50	0.33 (0.07 to 1.54)
RITA-2 199714	26/504	13/514	2.04 (1.06 to 3.92)
AVERT 199915	4/177	4/164	1.16 (0.32 to 4.24)
Death
Parisi 1992 17	0/105	1/107	0.50 (0.01 to 14.89)
Sievers 199316	0/44	1/44	0.50 (0.01 to 14.20)
MASS 199518	1/72	0/72	2.03 (0.07 to 59.51)
Folland 199713	2/51	1/50	1.96 (0.18 to 20.95)
RITA-2 199714	11/504	7/514	1.60 (0.63 to 4.10)
AVERT 199915	1/177	1/164	0.92 (0.06 to 14.69)
Need for PCTA
Parisi 1992 17	16/105	11/107	1.48 (0.72 to 3.04)
Sievers 199316	5/44	7/44	0.71 (0.25 to 2.08)
MASS 199518	27/72	3/72	9.00 (2.86 to 28.35)
Folland 199713	11/51	8/50	1.35 (0.59 to 3.07)
RITA-2 199714	62/504	101/514	0.63 (0.47 to 0.84)
AVERT 199915	18/177	21/164	1.08 (0.60 to 1.96)
CABG
Parisi 1992 17	7/105	0/107	15.28 (0.88 to 264.00)
Sievers 199316	2/44	2/44	1.00 (0.15 to 6.79)
MASS 199518	8/72	4/72	2.00 (0.63 to 6.35)
Folland 199713	3/51	1/50	2.94 (0.32 to 27.34)
RITA-2 199714	40/504	30/514	1.36 (0.86 to 2.15)
AVERT 199915	9/177	2164	4.17 (0.91 to 19.01)

^*The AVERT study did not report number of patients with angina. 

CABG: coronary artery bypass graft.